Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal stimulation.

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle atrophy (SMA) progression and could be applied to other motoneuron diseases, ...

Researchers reported what they called the first evidence that a spine-stimulating implant might aid neurodegenerative ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop.

Researchers have shown that a spinal cord-stimulating implant, originally used for paralysis, may help restore muscle ...

Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.